Cooley advised Therachon Holding, a clinical-stage biotechnology company focused on rare diseases, in its agreement to sell to Pfizer, an innovative biopharmaceutical company discovering, developing and providing medicines, vaccines and consumer healthcare products, for up to $810 million. Partners Ryan Sansom and Michal Berkner led the Cooley team.
